Aisthesis Medical, a healthtech startup based in the United Kingdom with 100% Greek DNA, which participated in the InnoHealth Forum in 2024 and is a client of HealthHub, has announced the successful completion of a €1 million pre-seed funding round.
Founded in 2022 by Ioannis Gouzionis — who was a keynote speaker at the Innovent Forum in 2023 — Vassilis Dimakopoulos, and Sotiris Liliopoulos, the company develops AI-powered clinical decision support software.
The funding round was led by TwinPath Ventures (London, UK) with participation from TECS Capital (Thessaloniki, Greece).
The new capital will be used to finalize VIOSync SPI, an AI-based clinical decision support platform that predicts the onset of sepsis within the next 48 hours.
Sepsis: A Global Health Emergency
Sepsis remains one of the most urgent global healthcare challenges, causing over 11 million deaths annually and costing national healthcare systems billions.
Early prediction, diagnosis, and intervention are critical — yet frontline clinical teams often lack the tools to recognize the early onset of sepsis before a patient’s condition deteriorates.
The Solution: VIOSync SPI
VIOSync SPI bridges this gap by safely integrating multiple types of patient data from hospital electronic health records, creating a digital twin that represents the evolving physiology of the patient.
Using explainable AI algorithms, the platform predicts sepsis up to 48 hours before its onset.
In doing so, VIOSync SPI provides clinical teams with timely alerts, accompanied by transparent risk factors and data-driven insights, enabling earlier intervention and ultimately saving lives.
Next Steps and Objectives
This investment will support Aisthesis Medical’s mission to equip healthcare professionals with reliable and explainable AI tools capable of preventing life-threatening conditions such as sepsis.
The funds will be used to obtain CE MDR certification for VIOSync SPI as a medical software device and to conduct additional validation clinical studies in leading hospitals in the UK and the EU.
The company also plans to expand its team to scale product reach and prepare for pilot implementations within the NHS and other international healthcare systems.
Statements from the Founders and Investors
Ioannis Gouzionis, Co-Founder & CEO of Aisthesis Medical, stated:
“I have personally experienced sepsis twice in my life and know firsthand how quickly stability can turn into crisis — and how much earlier diagnosis can change the outcome.
With VIOSync, we give clinical teams a reliable and explainable way to anticipate risk before deterioration symptoms appear, enabling faster decisions and ultimately saving lives.
This funding is a strong validation of our mission and will help us accelerate both product certification and clinical deployment.”
Katie Lockwood, Partner at TwinPath Ventures, commented:
“Sepsis is an ‘invisible threat’ for which reliable tools for early prediction and clinician alerting have long been missing.
Aisthesis Medical’s combination of explainable AI and digital twin technology through multimodal medical data integration is unique and could set a new standard in sepsis care and management.
We’re proud to support this exceptional team as they advance toward medical certification and market entry.”
Antonis Ilias, Partner at TECS Capital, added:
“Our support for Aisthesis Medical as the first investment of TECS Capital II reflects the kind of deep tech entrepreneurship with social impact that we represent.
Transforming sepsis prediction through explainable AI goes beyond innovation — it represents a life-saving shift in clinical practice.
With clinical validation already underway in the UK and EU, and a disciplined path toward CE MDR approval, we’re proud to back an outstanding founding team on their journey to bring this product to market.”
Stay tuned for more updates!